Evidence map›Paper›PMID 30103980›Full record

ArticleThe Lancet. Global health2018

Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study.

Molly F Franke, Ralph Ternier, J Gregory Jerome, Wilfredo R Matias, Jason B Harris, Louise C Ivers

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Global health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Impact of a multi-pronged cholera intervention in an endemic setting.medRxiv : the preprint server for health sciences · 2024
    Article
  10. Article
  11. Effectiveness of the Euvichol® oral cholera vaccine at 2 years: A case-control and bias-indicator study in Haiti.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Article
  12. Article
  13. Article
  14. A polyvalent multiepitope protein cross-protects againstProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Molly F FrankeDepartment of Global Health and Social Medicine, Boston, MA, USA. Electronic address: molly_franke@hms.harvard.edu.
Ralph TernierHarvard Medical School, Boston, MA, USA; Partners In Health, Port au Prince, Haiti, MA, USA.
J Gregory JeromeHarvard Medical School, Boston, MA, USA; Partners In Health, Port au Prince, Haiti, MA, USA.
Wilfredo R MatiasDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Jason B HarrisDepartment of Pediatrics, Boston, MA, USA; Division of Pediatric Global Health, Massachusetts General Hospital, Boston, MA, USA.
Louise C IversDepartment of Global Health and Social Medicine, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Partners In Health, Port au Prince, Haiti, MA, USA; Center for Global Health, Massachusetts General Hospital, Boston, MA, USA.
Partners In Health · USBrigham and Women's Hospital · USCenter for Global Health · USMassachusetts General Hospital · US

Funding

Immune Responses to Vibrio cholerae infection and vaccination in HaitiR01AI099243 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B, IVERS, LOUISE C. · 2012 to 2022
$7.9M
NIAID NIH HHS R01 AI099243
6 · The paper itself

Abstract

backgroundNo study of long-term protection following killed oral cholera vaccination has been done outside of the historically cholera-endemic areas of south Asia, or has examined protection after a single-dose vaccination regimen. To address this, we examined the duration of protection of the standard two-dose regimen and an incomplete regimen of one dose up to 4 years after vaccination in Haiti.

methodsIn the setting of two-dose vaccination campaigns with a killed, bivalent, whole-cell oral cholera vaccination, we did a case-control study from October, 2012 through November, 2016. Eligible participants were required to be resident in the vaccine catchment area (Artibonite Department or Central Department) where they were recruited at the start of the study; and be eligible for the vaccination campaign (ie, aged ≥12 months, not pregnant, and living in the region at the time of the vaccine campaign). Patients with cholera had a positive stool culture and were recruited from cholera treatment centres. Community controls were matched to people with cholera by age group, time, and neighbourhood. We did adjusted matched regression analyses to calculate vaccine effectiveness and examine heterogeneity in effectiveness over time. The primary outcome was the effectiveness of one and two oral cholera doses as compared with zero doses from 2 months to 48 months after vaccination, measured by self reporting.

findingsAmong 178 people assigned to the case group and 706 people assigned to the control group, we found no evidence that two-dose effectiveness decreased during follow-up. In adjusted analyses, the average cumulative 4 year effectiveness for two doses was 76% (95% CI 59-86). In contrast, single-dose effectiveness decreased over time in a log-linear fashion, with a predicted vaccine effectiveness of 79% at the end of 12 months (95% CI 43-93), which declined to zero before the end of the second year.

interpretationIn a setting of epidemic and newly endemic cholera in Haiti, single-dose vaccination with killed, bivalent, whole-cell oral cholera vaccination provided short-term protection; however, vaccination with two doses was required for long-term protection, which lasted up to 4 years after vaccination. These results add to the evidence in support of the use of killed, bivalent, whole-cell oral cholera vaccination as part of comprehensive cholera control plans.

fundingUS National Institute of Allergy and Infectious Diseases of the National Institutes of Health and the Bill & Melinda Gates Foundation.

Indexed as

Administration, OralAdolescentAdultAgedAged, 80 and overCase-Control StudiesChildChild, PreschoolCholeraCholera VaccinesFemaleHaitiHumansImmunization ProgramsImmunization, SecondaryInfantCholera VaccinesVaccines, Inactivated

Identifiers

PMID30103980
PMCPMC6190920
OpenAlexW2887700426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.